Practical guidelines for the use of NESP in treating renal anaemia

Nephrology Dialysis Transplantation

Volumn 16, Issue SUPPL. 3, 2001, Pages 22-28

  Aljama, P ^a   Bommer, J ^a   Canaud, B ^a   Carrera, F ^a   Eckardt, K U ^a   Horl W H ^a   Krediet, R T ^a   Locatelli, F ^a   Macdougall, I C ^a   Wikstrom B ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anaemia; Chronic kidney disease; Chronic renal failure; Chronic renal insufficiency; Darbepoetin alfa; End stage renal disease; Erythropoietin; NESP; Pre dialysis

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANTIBODY DETECTION; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG MONITORING; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; IRON THERAPY; KIDNEY TRANSPLANTATION; PERIOPERATIVE PERIOD; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOSIS; UREMIA; VASCULAR ACCESS;

EID: 0034949212     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.suppl_3.22     Document Type: Article

References (29)

1. Novel erythropiesis stimulating protein (NESP) has a longer serum half-life and greater in vivi biological activity than recombinant human erythropoient (rHuEPO)
2. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients
3. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (Hb) in ESRD patients when administered once weekly or once every other week
4. European best practice guidelines for the management of anaemia in patients guidlines for the management of anaemia in patients with chronic renal failure
5. The pharmacokinetics of novel erythopoiesis stimulating protein (NESP) in pediatric patients with chronic renal failure (CRF) or end-stage renal disease
6. Pharmacokinetics of recombinant human erythropoietin applied subcutaneoulsy to childern with chronic renal failure
7. Pharmacokinetics of recombinant human erythropoietin in children with chronic renal failure
8. The second international reference preparation of erythropoietin, human, urinary, for bioassay
9. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin
10. Rational design of novel erythropoiesis stimulating protein (ARANESP™): A super-sialated erythropoietin with increased biological activity
11. Development and characterization of novel erythropoiesis stimulating protein (NESP)
12. The role of carbohydrate on the biological activity of erythropoietin
13. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in ESRD patients
14. Optimizing epoetin therapy in end-stage renal disease: The case for subcutaneous administration
15. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO)
16. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency erythropoietin (rHuEPO)
17. Indications and contraindications for recombinant human erythropoietin treatment. Results in hemodialysis patients
18. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis
19. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial
20. Multicenter trial of erythropoietin in patients on peritoneal dialysis
21. Safety and efficacy of recombinant human erythropoietin treatment of anaemia associated with multiple myeloma in haemodialysed patients
22. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO)
23. Blood pressure after three different forms of correction of anemia in hemodialysis
24. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis
25. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hgb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in dialysis patients
26. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers
27. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease
28. Novel erythropoiesis stimulating protein